Best of ASCO - 2014 Annual Meeting



Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Sex is a strong prognostic factor for overall survival in advanced non small cell lung cancer patients and should be considered for survival rates estimations.

Metastatic Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Metastatic

2019 ASCO Annual Meeting

Abstract No:

J Clin Oncol 37, 2019 (suppl; abstr e20580)

Author(s): Miguel Barquin, Francisco Garcia-Garcia, Atocha Romero, Enric Carcereny, Delvys Rodriguez-Abreu, Rafael Lopez Castro, Maria Guirado, Carlos Camps, Joaquim Bosch-Barrera, Bartomeu Massuti, Ana Laura Ortega, Jose-Luis Gonzalez-Larriba, Rosario Garcia-Campelo, Manuel Domine, Sara Agraso Busto, María Ángeles Sala, Juana Oramas, Reyes Bernabé, Mariano Provencio-Pulla; Hospital universitario Puerta de Hierro, Majadahonda, Spain; Bioinformatics & Biostatistics Unit, Principe Felipe Research center, Valencia, Spain; Hospital Universitario Puerta De Hierro-Majadahonda, Madrid, Spain; Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, B.ARGO GROUP Badalona Applied Research Group in Oncology, Badalona, Spain; Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain; Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Hospital General de Elche, Elche, Alicante, Spain; Servicio de Oncología Médica, Hospital General de Valencia, Valencia, Spain; Institut Catala d'Oncologia, Universitary Hospital Dr. Josep Trueta, Girona, Spain; Alicante University Hospital ISABIAL, Alicante, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Clinico San Carlos, Madrid, Spain; University Hospital A Coruña, Coruña, Spain; Oncology Department and Translational Oncology Division, University Hospital Fundacion Jimenez Diaz, Madrid, Spain; Complejo Hospitalario Universitario de Vigo, Vigo, Spain; University Hospital of Basurto, Bilbao, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Valme, Seville, Spain; Hospital Universitario Puerta de Hierro, Madrid, Spain

Abstract Disclosures


Background: Biological differences between sexes have a major impact on disease and treatment outcome. In this paper, we evaluate the prognostic value of sex in advance NSCLC in the context of real world data. Methods: Clinical data from stage IV non-small cell lung cancer (NSCLC) patients from Hospital Puerta de Hierro (HPH) was retrieved from Electronical records using BigData Analytics (N = 387). In addition, data from Spanish Lung Cancer Group (GECP) Tumor Registry (N = 1382) and from a published study through cBioPortal (MSK) (N = 601) was analyzed. Survival curves were estimated using Kaplan-Meier analysis. Cox proportional hazards regression model was used to assess the prognostic factor of sex. Results: The median overall survival (OS) time was 12 months for men and 19 months for women (P < 0.001). Similarly, women with stage IV NSCLC harbouring an EGFR sensitizing mutation lived longer than men (median overall survival was 19 months for men and 32 months for women). Gender effect was still significant after adjustment by Cox regression for other potential confounding factors. The adjusted hazard ratios for sex were 0.65 (95% CI, 0.51-0.83), 0.84 (95% CI, 0.66-1.1) and 0.76 (95% CI, 0.65-0.88) for HPH, MSK and GECP data sets respectively. Similarly, in EGFR positive population adjusted hazard ratios for sex were 0.53 (95% CI, 0.25-1.1), 0.59 (95% CI, 0.35-0.98) and 0.60 (95% CI, 0.45-0.86) for HPH, MSK and GECP data sets respectively. Conclusions: Using real world data we confirm previous finding that among stage IV NSCLC patients, women live almost twice longer than men. This effect persisted after adjusting for several factors highlighting the fact that survival rates estimations which are usually performed grouping men and women together might not be accurate enough for prognosis assessments

Other Abstracts in this Sub-Category:


1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer


2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer


3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer